The effect of Elettaria cardamomum (cardamom) on the metabolic syndrome: Narrative review

Document Type : Review Article


1 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

2 Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

3 Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran


Metabolic syndrome (MetS), as a health-threatening factor, consists of various symptoms including insulin resistance, high blood sugar, hypertension, dyslipidemia, inflammation, and abdominal obesity that raise the risk of diabetes mellitus and cardiovascular disease. Cardiovascular diseases are important causes of mortality among the world population. Recently, there has been a growing interest in using phytomedicine and natural compounds in the prevention and treatment of various diseases. The data was gathered by searching various standard electronic databases (Google Scholar, Scopus, Web of Science, and PubMed) for English articles with no time limitations. All in vivo, in vitro, and clinical studies were included. Elettaria cardamomum (cardamom) is a rich source of phenolic compounds, volatile oils, and fixed oils. Cardamom and its pharmacologically effective substances have shown broad-spectrum activities including antihypertensive, anti-oxidant, lipid-modifying, anti-inflammatory, anti-atherosclerotic, anti-thrombotic, hepatoprotective, hypocholesterolemic, anti-obesity, and antidiabetic effects. This review aims to highlight the therapeutic effects of cardamom on MetS and its components including diabetes, hyperlipidemia, obesity, and high blood pressure as well as the underlying mechanisms in the management of MetS. Finally, it can be stated that cardamom has beneficial effects on the treatment of MetS and its complications.


1. Mollazadeh H, Hosseinzadeh H. Cinnamon effects on metabolic syndrome: a review based on its mechanisms. Iran J Basic Med Sci 2016; 19: 1258–1270.
2. Tousian Shandiz H, Razavi BM, Hosseinzadeh H. Review of Garcinia mangostana and its xanthones in metabolic syndrome and related complications. Phytother Res 2017; 31: 1173-1182.
3. Hassani FV, Shirani K, Hosseinzadeh H. Rosemary (Rosmarinus officinalis) as a potential therapeutic plant in metabolic syndrome: a review. Naunyn Schmiedebergs Arch Pharmacol 2016; 389: 931-949.
4. Baxter AJ, Coyne T, McClintock C. Dietary patterns and metabolic syndrome-a review of epidemiologic evidence. Asia Pac J Clin Nutr 2006; 15: 134-142.
5. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018; 20: 1-8.
6. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011; 94: 58-65.
7. Beigh SH, Jain S. Prevalence of metabolic syndrome and gender differences. Bioinformation 2012; 8: 613-616.
8. Al Rashdan I, Al Nesef Y. Prevalence of overweight, obesity, and metabolic syndrome among adult Kuwaitis: results from community-based national survey. Angiology 2010; 61: 42-48.
9. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index; United States, 2003-2006. Natl Health Stat Report 2009: 1-7.
10. Janus ED, Laatikainen T, Dunbar JA, Kilkkinen A, Bunker SJ, Philpot B, et al. Overweight, obesity and metabolic syndrome in rural southeastern Australia. Med J Aust 2007; 187: 147-152.
11. Magkos F, Yannakoulia M, Chan JL, Mantzoros CS. Management of the metabolic syndrome and type 2 diabetes through lifestyle modification. Annu Rev Nutr 2009; 29: 223-256.
12. Hosseini A, Hosseinzadeh H. A review on the effects of Allium sativum (Garlic) in metabolic syndrome. J Endocrinol Invest 2015; 38: 1147-1157.
13. Hosseinzadeh H, Nassiri-Asl M. Review of the protective effects of rutin on the metabolic function as an important dietary flavonoid. J Endocrinol Invest 2014; 37: 783-788.
14. Razavi BM, Hosseinzadeh H. Saffron: a promising natural medicine in the treatment of metabolic syndrome. J Sci Food Agric 2017; 97: 1679-1685.
15. Akaberi M, Hosseinzadeh H. Grapes (Vitis vinifera) as a potential candidate for the therapy of the metabolic syndrome. Phytother Res 2016; 30: 540-556.
16. Rahman MM, Alam MN, Ulla A, Sumi FA, Subhan N, Khan T, et al. Cardamom powder supplementation prevents obesity, improves glucose intolerance, inflammation and oxidative stress in liver of high carbohydrate high fat diet induced obese rats. Lipids Health Dis 2017; 16: 1-12.
17. Vahabzadeh M, Amiri N, Karimi G. Effects of silymarin on metabolic syndrome: a review. J Sci Food Agric 2018; 98: 4816-4823.
18. Razavi B, Hosseinzadeh H. A review of the effects of Nigella sativa L. and its constituent, thymoquinone, in metabolic syndrome. J Endocrinol Invest 2014; 37: 1031-1040.
19. Fadishei M, Ghasemzadeh Rahbardar M, Imenshahidi M, Mohajeri A, Razavi BM, Hosseinzadeh H. Effects of Nigella sativa oil and thymoquinone against bisphenol A‐induced metabolic disorder in rats. Phytother Res 2021; 35: 2005-2024.
20. Tabeshpour J, Razavi BM, Hosseinzadeh H. Effects of avocado (Persea americana) on metabolic syndrome: A comprehensive systematic review. Phytother Res 2017; 31: 819-837.
21. Yarmohammadi F, Ghasemzadeh Rahbardar M, Hosseinzadeh H. Effect of eggplant (Solanum melongena) on the metabolic syndrome: A review. Iran J Basic Med Sci 2021; 24: 420-427.
22. Tabeshpour J, Imenshahidi M, Hosseinzadeh H. A review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndrome. Iran J Basic Med Sci 2017; 20: 557-568.
23. Ravindran P, Madhusoodanan K. Cardamom: the genus Elettaria: CRC Press; 2002.
24. Gopalakrishnan M, Narayanan C, Grenz M. Nonsaponifiable lipid constituents of Cardamom. J Agric Food Chem 1990; 38: 2133-2136.
25. Duke JA. Handbook of phytochemical constituent grass, herbs and other economic plants. CRC press LLC; 1992.p. 239-240.
26. Anwar F, Abbas A, Alkharfy KM. Cardamom (Elettaria cardamomum Maton) Oils.  In: Preedy VR, editor. Essential oils in food preservation, flavor and safety. Academic Press; 2016.p. 295-301.
27. Alam A, Rehman NU, Ansari MN, Palla AH. Effects of essential oils of Elettaria cardamomum grown in India and Guatemala on gram-negative bacteria and gastrointestinal disorders. Molecules 2021; 26: 2546.
28. Kaushik P, Goyal P, Chauhan A, Chauhan G. In vitro evaluation of antibacterial potential of dry fruitextracts of Elettaria cardamomum Maton (Chhoti Elaichi). Iran J Pharm Sci 2010; 9: 287–292.
29. Jesylne P, Soundarajan S, Murthykumar K, Meenakshi M. The role of cardamom oil in oral health: A short review. Res J Pharm Technol 2016; 9: 272-274.
30. Kumari S, Dutta A. Protective effect of Elettaria cardamomum (L.) Maton against Pan masala induced damage in lung of male Swiss mice. Asian Pac J Trop Med 2013; 6: 525-531.
31. Al-Zuhair H, El-Sayeh B, Ameen H, Al-Shoora H. Pharmacological studies of cardamom oil in animals. Pharmacol Res 1996; 34:79-82.
32. Jamal A, Javed K, Aslam M, Jafri M. Gastroprotective effect of cardamom, Elettaria cardamomum Maton. fruits in rats. J Ethnopharmacol 2006; 103: 149-153.
33. Saeed A, Sultana B, Anwar F, Mushtaq M, Alkharfy KM, Gilani A-H. Antioxidant and antimutagenic potential of seeds and pods of green cardamom (Elettaria cardamomum). Int J Pharmacol 2014; 10: 461-469.
34. Souissi M, Azelmat J, Chaieb K, Grenier D. Antibacterial and anti-inflammatory activities of cardamom (Elettaria cardamomum) extracts: Potential therapeutic benefits for periodontal infections. Anaerobe 2020; 61: 102089.
35. Ahmed AS, Ahmed QU, Saxena AK, Jamal P. Evaluation of in vitro antidiabetic and anti-oxidant characterizations of Elettaria cardamomum (L.) Maton (Zingiberaceae), Piper cubeba L. f.(Piperaceae), and Plumeria rubra L.(Apocynaceae). Pak J Pharm Sci 2017; 30: 113-126.
36. Goyal SN, Sharma C, Mahajan UB, Patil CR, Agrawal YO, Kumari S, et al. Protective effects of cardamom in isoproterenol-induced myocardial infarction in rats. Int J Mol Sci 2015; 16: 27457-27469.
37. Elguindy NM, Yacout GA, El Azab EF, Maghraby HK. Chemoprotective effect of Elettaria cardamomum against chemically induced hepatocellular carcinoma in rats by inhibiting NF-κB, oxidative stress, and activity of ornithine decarboxylase. S Afr J Bot 2016; 105: 251-258.
38. Blaton VH, Korita I, Bulo A. How is metabolic syndrome related to dyslipidemia? Biochem Med 2008; 18: 14-24.
39. Ruotolo G, Howard BV. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 2002; 4: 494-500.
40. Cefalu WT. Diabetic dyslipidemia and the metabolic syndrome. Diabetes Metab Syndr 2008; 2: 208-222.
41. Jeong H, Baek S-Y, Kim SW, Park E-J, Lee J, Kim H, et al. C reactive protein level as a marker for dyslipidaemia, diabetes and metabolic syndrome: results from the Korea National Health and Nutrition Examination Survey. BMJ open 2019; 9: e029861.
42. den Engelsen C, Koekkoek PS, Gorter KJ, van den Donk M, Salomé PL, Rutten GE. High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a cross-sectional analysis. Cardiovasc Diabetol 2012; 11: 1-7.
43. Fatemeh Y, Siassi F, Rahimi A, Koohdani F, Doostan F, Qorbani M, et al. The effect of cardamom supplementation on serum lipids, glycemic indices and blood pressure in overweight and obese pre-diabetic women: a randomized controlled trial. J Diabetes Metab Disord 2017; 16: 1-9.
44. Aghasi M, Koohdani F, Qorbani M, Nasli‐Esfahani E, Ghazi‐Zahedi S, Khoshamal H, et al. Beneficial effects of green cardamom on serum SIRT1, glycemic indices and triglyceride levels in patients with type 2 diabetes mellitus: a randomized double‐blind placebo controlled clinical trial. J Sci Food Agric 2019; 99: 3933-3940.
45. Kazemi S, Yaghooblou F, Siassi F, Rahimi Foroushani A, Ghavipour M, Koohdani F, et al. Cardamom supplementation improves inflammatory and oxidative stress biomarkers in hyperlipidemic, overweight, and obese pre‐diabetic women: A randomized double‐blind clinical trial. J Sci Food Agric 2017; 97: 5296-5301.
46. Bhat GN, Nayak N, Vinodraj K, Chandralekha N, Mathai P, Cherian J. Comparison of the efficacy of cardamom (Elettaria cardamomum) with pioglitazone on dexamethasone-induced hepatic steatosis, dyslipidemia, and hyperglycemia in albino rats. J Adv Pharm Technol Res 2015; 6: 136-140.
47. Nagashree S, Archana KK, Srinivas P, Srinivasan K, Sowbhagya HB. Anti‐hypercholesterolemic influence of the spice cardamom (Elettaria cardamomum) in experimental rats. J Sci Food Agric 2017; 97: 3204-3210.
48. Cho K-H. 1, 8-cineole protected human lipoproteins from modification by oxidation and glycation and exhibited serum lipid-lowering and anti-inflammatory activity in zebrafish. BMB Rep 2012; 45: 565-570.
49. Razavi BM, Abazari AR, Rameshrad M, Hosseinzadeh H. Carnosic acid prevented olanzapine-induced metabolic disorders through AMPK activation. Mol Biol Rep 2020; 47: 7583-7592.
50. Malekzadeh S, Heidari MR, Razavi BM, Rameshrad M, Hosseinzadeh H. Effect of safranal, a constituent of saffron, on olanzapine (an atypical antipsychotic) induced metabolic disorders in rat. Iran J Basic Med Sci 2019; 22: 1476-1482.
51. Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res 2016; 118: 1723-1735.
52. Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res 2016; 118: 1752-1770.
53. Jiang SZ, Lu W, Zong XF, Ruan HY, Liu Y. Obesity and hypertension. Exp Ther Med 2016; 12: 2395-2399.
54. Xanthopoulos M, Tapia IE. Obesity and common respiratory diseases in children. Paediatr Respir Rev 2017; 23: 68-71.
55. Malti N, Merzouk H, Merzouk S, Loukidi B, Karaouzene N, Malti A, et al. Oxidative stress and maternal obesity: feto-placental unit interaction. Placenta 2014; 35: 411-416.
56. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169-2180.
57. Madhikarmi NL, Singh PP, Khatun T. Lipid peroxidation and anti-oxidant status in male and female patients with type 1 and type 2 diabetes mellitus. Med Phoenix 2016; 1: 10-14.
58. Molnár D, Decsi T, Koletzko B. Reduced anti-oxidant status in obese children with multimetabolic syndrome. Int J Obes 2004; 28: 1197-1202.
59. Quiñones M, Martínez-Grobas E, Fernø J, Pérez-Lois R, Seoane LM, Al Massadi O. Hypothalamic actions of SIRT1 and SIRT6 on energy balance. Int J Mol Sci 2021; 22: 1430.
60. Al Massadi O, Quiñones M, Lear P, Dieguez C, Nogueiras R. The brain: A new organ for the metabolic actions of SIRT1. Horm Metab Res 2013; 45: 960-966.
61. Ramadori G, Fujikawa T, Fukuda M, Anderson J, Morgan DA, Mostoslavsky R, et al. SIRT1 deacetylase in POMC neurons is required for homeostatic defenses against diet-induced obesity. Cell Metab 2010; 12: 78-87.
62. Velásquez DA, Martínez G, Romero A, Vázquez MJ, Boit KD, Dopeso-Reyes IG, et al. The central sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin. Diabetes 2011; 60: 1177-1185.
63. dos Santos Costa C, Hammes TO, Rohden F, Margis R, Bortolotto JW, Padoin AV, et al. SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis. Obes Surg 2010; 20: 633-639.
64. Kim M-S, Pak YK, Jang P-G, Namkoong C, Choi Y-S, Won J-C, et al. Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat Neurosci 2006; 9: 901-906.
65. Susanti VY, Sasaki T, Yokota‐Hashimoto H, Matsui S, Lee YS, Kikuchi O, et al. Sirt1 rescues the obesity induced by insulin‐resistant constitutively‐nuclear FoxO1 in POMC neurons of male mice. Obesity 2014; 22: 2115-2119.
66. Daneshi-Maskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badri-Fariman M, et al. Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial. Nutr Metab 2018; 15: 1-12.
67. Cheshmeh S, Elahi N, Ghayyem M, Mosayebi E, Moradi S, Pasdar Y, et al. Effects of green cardamom supplementation on obesity and diabetes gene expression among obese women with polycystic ovary syndrome; A double blind randomized controlled trial. Research Square, 2021. DOI: 10.21203/
68. Verma S, Jain V, Katewa S. Blood pressure lowering, fibrinolysis enhancing and anti-oxidant activities of cardamom (Elettaria cardamomum). Indian J Biochem Biophys 2009; 46: 503-506.
69. Gilani AH, Jabeen Q, Khan A-u, Shah AJ. Gut modulatory, blood pressure lowering, diuretic and sedative activities of cardamom. J Ethnopharmacol 2008; 115: 463-472.
70. Sabino CKB, Ferreira‐Filho ES, Mendes MB, da Silva‐Filho JC, Ponte MPTR, Moura LHP, et al. Cardiovascular effects induced by α‐terpineol in hypertensive rats. Flavour Fragr J 2013; 28: 333-339.
71. Ribeiro TP, Porto DL, Menezes CP, Antunes AA, Silva DF, De Sousa DP, et al. Unravelling the cardiovascular effects induced by α‐terpineol: A role for the nitric oxide–cGMP pathway. Clin Exp Pharmacol Physiol 2010; 37: 811-816.
72. Lahlou S, Figueiredo AF, Magalhães PJC, Leal-Cardoso JH. Cardiovascular effects of 1, 8-cineole, a terpenoid oxide present in many plant essential oils, in normotensive rats. Can J Physiol Pharmacol 2002; 80: 1125-1131.
73. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
74. Du X, Edelstein D, Obici S, Higham N, Zou M-H, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. The Journal of clinical investigation 2006; 116: 1071-1080.
75. Jellinger PS. Metabolic consequences of hyperglycemia and insulin resistance. Clinical cornerstone 2007; 8: S30-S42.
76. Furnary AP, Wu Y. Clinical effects of hyperglycemia in the cardiac surgery population: the Portland Diabetic Project. Endocrine Practice 2006; 12: 22-26.
77. Planavila A, Iglesias R, Giralt M, Villarroya F. Sirt1 acts in association with PPARα to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc Res 2011; 90: 276-284.
78. Kitada M, Koya D. SIRT1 in type 2 diabetes: mechanisms and therapeutic potential. Diabetes Metab J 2013; 37: 315–325.
79. Kitada M, Kume S, Kanasaki K, Takeda-Watanabe A, Koya D. Sirtuins as possible drug targets in type 2 diabetes. Curr Drug Targets 2013; 14: 622-636.
80. Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab 2011; 13: 11-22.
81. Paul K, Bhattacharjee P, Chatterjee N, Pal TK. Nanoliposomes of supercritical carbon dioxide extract of small cardamom seeds redresses type 2 diabetes and hypercholesterolemia. Recent Pat Biotechnol 2019; 13: 284-303.
82. Gomaa AA, Makboul RM, El-Mokhtar MA, Abdel-Rahman EA, Ahmed IA, Nicola MA. Terpenoid-rich Elettaria cardamomum extract prevents Alzheimer-like alterations induced in diabetic rats via inhibition of GSK3β activity, oxidative stress and pro-inflammatory cytokines. Cytokine 2019; 113: 405-416.
83. Paul K, Chakraborty S, Mallick P, Bhattacharjee P, Pal TK, Chatterjee N, et al. Supercritical carbon dioxide extracts of small cardamom and yellow mustard seeds have fasting hypoglycaemic effects: diabetic rat, predictive iHOMA2 models and molecular docking study. Br J Nutr 2021; 125: 377-388.
84. Mohamed EAH, Siddiqui MJA, Ang LF, Sadikun A, Chan SH, Tan SC, et al. Potent α-glucosidase and α-amylase inhibitory activities of standardized 50% ethanolic extracts and sinensetin from Orthosiphon stamineus Benth as anti-diabetic mechanism. BMC Complement Altern Med 2012; 12: 1-7.